Details for Patent: 10,758,534
✉ Email this page to a colleague
Which drugs does patent 10,758,534 protect, and when does it expire?
Patent 10,758,534 protects TRIKAFTA (COPACKAGED) and is included in two NDAs.
This patent has forty-six patent family members in twenty-nine countries.
Summary for Patent: 10,758,534
| Title: | Modulators of cystic fibrosis transmembrane conductance regulator |
| Abstract: | The present invention features a compound of formula I: ##STR00001## or a pharmaceutically acceptable salt thereof, where R.sub.1, R.sub.2, R.sub.3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof. |
| Inventor(s): | Miller; Mark Thomas (San Diego, CA), Anderson; Corey (San Diego, CA), Arumugam; Vijayalaksmi (San Marcos, CA), Bear; Brian Richard (Carlsbad, CA), Binch; Hayley Marie (Encinitas, CA), Clemens; Jeremy J. (San Diego, CA), Cleveland; Thomas (San Diego, CA), Conroy; Erica (Columbus, OH), Coon; Timothy Richard (Carlsbad, CA), Frieman; Bryan A. (La Jolla, CA), Grootenhuis; Peter Diederik Jan (San Diego, CA), Gross; Raymond Stanley (Poway, CA), Hadida-Ruah; Sara Sabina (La Jolla, CA), Khatuya; Haripada (San Diego, CA), Joshi; Pramod Virupax (San Diego, CA), Krenitsky; Paul John (San Diego, CA), Lin; Chun-Chieh (San Diego, CA), Marelius; Gulin Erdogan (San Diego, CA), Melillo; Vito (Escondido, CA), McCartney; Jason (Cardiff by the Sea, CA), Nicholls; Georgia McGaughey (Winchester, MA), Pierre; Fabrice Jean Denis (La Jolla, CA), Silina; Alina (San Diego, CA), Termin; Andreas P. (Encinitas, CA), Uy; Johnny (San Diego, CA), Zhou; Jinglan (San Diego, CA) |
| Assignee: | Vertex Pharmaceuticals Incorporated (Boston, MA) |
| Application Number: | 16/258,024 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 10,758,534
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | GRANULES;ORAL | 217660-001 | Apr 26, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO | ⤷ Try a Trial | ||
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | GRANULES;ORAL | 217660-002 | Apr 26, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO | ⤷ Try a Trial | ||
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | TABLET;ORAL | 212273-002 | Jun 8, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR | ⤷ Try a Trial | ||
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | TABLET;ORAL | 212273-001 | Oct 21, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR | ⤷ Try a Trial | ||
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | TABLET;ORAL | 212273-001 | Oct 21, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR | ⤷ Try a Trial | ||
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | TABLET;ORAL | 212273-001 | Oct 21, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,758,534
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 102180 | ⤷ Try a Trial | |||
| Australia | 2015328174 | ⤷ Try a Trial | |||
| Australia | 2020220185 | ⤷ Try a Trial | |||
| Australia | 2023201404 | ⤷ Try a Trial | |||
| Brazil | 112017007167 | ⤷ Try a Trial | |||
| Canada | 2963792 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
